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hyperglycemia and resultant tissue
damage, it seems that one might want to
get by with needing as little insulin as
possible, in order to minimize its inhibition
of the life span-extending effects identified
in animal models. The present study may
also have implications for understanding
effects of calorie restriction, a condition
that prolongs life in essentially every
organism examined (Bishop andGuarente,
2007). By identifying a specific life span-
inhibitory effect of glucose, its results raise
the question of whether the effects of
limiting calories and glucose might be
distinguishable. Evidently, we can’t have
our cake and eat it too just yet, but hope
remains that a better understanding of
how low insulin activity increases life span
could allow these prolongevity mecha-
nisms to be harnessed without impairing
the essential activities of insulin. In the
meantime, this work provides additional
motivation to skip dessert.
REFERENCES
Bishop, N.A., and Guarente, L. (2007). Nat. Rev.
Genet. 8, 835–844.
Brownlee, M. (2005). Diabetes 54, 1615–1625.
Lee, S.-J., Murphy, C.T., and Kenyon, C. (2009).
Cell Metab. 10, this issue, 379–391.
Maeda, N., Funahashi, T., and Shimomura, I.
(2008). Clin. Pract. Endocrinol. Metab. 4, 627–634.
Russell, S.J., and Kahn, C.R. (2007). Nat. Rev. 8,
681–691.
Schlotterer, A., Kukudov, G., Bozorgmehr, F.,
Hutter, H., Du, X., Oikonomou, D., Ibrahim, Y.,
Pfisterer, F., Rabbani, N., Thornalley, et al..
(2009). Diabetes, in press. Published online August
12, 2009. 10.2337/db09-0567.
Schulz, T.J., Zarse, K., Voigt, A., Urban, N.,
Birringer, M., and Ristow, M. (2007). Cell Metab.
6, 280–293.
Shepherd, P.R., and Kahn, B.B. (1999). N. Engl.
J. Med. 341, 248–257.
Figure 1. Effects of Glucose on Insulin-like Signaling and Longevity
Glucose stimulates release of insulin, which induces glucose uptake. Insulin-like signaling also inhibits
FOXO/DAF-16, which positively regulates aqp-1 and other stress resistance and longevity genes. High
glucose levels may increase cellular ROS. In C. elegans, these events all appear to occur in the intestine,
although insulin-like signaling responses vary among tissues.
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Proopiomelanocortin (Pomc) neurons play a central role in energy homeostasis. Despite the complexity of
Pomc posttranslational processing, regulation of Pomc gene expression often takes center stage. Comple-
mentary papers that zero in on distinct carboxypeptidases (Plum et al., 2009; Wallingford et al., 2009) now
refocus the spotlight on regulated peptide cleavage.Hypothalamicproopiomelanocortin (Pomc)
neuronal circuits play a critical role in
tightly matching body weight to a fixed
set point, primarily by inhibiting appetite
and feeding behavior (Cone, 2005).
Multiple regulatory steps in Pomc biosyn-
thesis ultimately determine Pomc-derivedpeptide tone in the CNS in response to
hormonal, metabolic, and trans-synaptic
inputs toPomcneurons (Figure 1). Indeed,
Pomc has served as a paradigm for inves-
tigating posttranslational processing of
prohormones into multiple bioactive
peptides (Pritchard and White, 2007).Cell Metabolism 10Among the well-characterized enzymes
are the prohormone convertases subtil-
isin/kexin type PC1 and PC2, carboxy-
peptidase E (Cpe), and peptidylglycine
a-amidating monooxygenase (PAM).
Spontaneous loss-of-function mutations
in PCSK1 orCpe cause obesity in humans, November 4, 2009 ª2009 Elsevier Inc. 339
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PreviewsFigure 1. Integrated Signaling from Multiple Humoral and Neural Inputs Regulates Pomc Expression, Posttranslational Processing, and
Peptide Release from Axon Terminals
Constitutively nuclear FoxO1 has been implicated previously as a transcriptional repressor of Pomc. Evidence linking FoxO1 to inhibition of Cpe expression in
Pomc neurons illuminates a second pathway for this protean transcription factor to coordinatemetabolic signaling by inducing changes in themix ofmelanocortin
and b-Endorphin peptide isoforms cleaved from Pomc and released from secretory vesicles. The fate of neuropeptides in the extracellular space has received
relatively little attention compared to the earlier steps in their biosynthesis. A new study implicates Prcp in the degradation of biologically active a-MSH to inactive
a-MSH1–12, thereby limiting the stimulation of melanocortin receptors on target neurons and illustrating another regulated step in Pomc peptide processing that
mediates anorexigenic tone in Pomc neural circuits.and mice (fa/fa), respectively, but their
pleiotropic range of substrates compli-
cates the assignment of causation to any
single neuropeptide precursor. Addition-
ally, Pomc processing raises an intriguing
biological paradox due to the stoichio-
metric production ofmelanocortins,which
in the most simplistic terms activate Gs-
coupled receptors on target neurons to
inhibit feeding, and the opioid peptide
b-endorphin1–31, which activates Gi-
coupled receptors to stimulate feeding.
It is in this context that Plum and
colleagues writing in Nature Medicine
explored amolecular pathway linking fork-
head box-containing transcription factor
of the O subfamily type 1 (FoxO1) to Cpe-
mediated Pomc peptide processing in
hypothalamic Pomc neurons (Plum et al.,
2009). FoxO1 plays a coordinating role in
several well-explored developmental and
metabolic intracellular signaling programs
in response to insulin (Gross et al., 2008).
Constitutively nuclear FoxO1 is phosphor-
ylated via an insulin receptor-Irs1-Akt
pathway and then translocated to the
cytoplasmic compartment, thereby abro-
gating its function as a regulator of gene
expression (Fukuda et al., 2008). FoxO1’s
transcriptional valence depends on the
particular promoter context and recruit-
ment of coactivator or corepressor340 Cell Metabolism 10, November 4, 2009 ªcomplexes. Pomc itself has been impli-
cated as a target of nuclear FoxO1,
although the precise mechanism for its
inhibitory effect is controversial (Kitamura
et al., 2006; Yang et al., 2009) and studies
performed in transfected, heterologous
cell lines may not truly represent the
endogenous milieu present in Pomc
neurons. Moreover, the full set of physio-
logically relevant transcriptional targets
for FoxO1 apart from Pomc and the genes
encoding neuropeptide Y (NPY) and
Agouti-related protein (Agrp) (Kim et al.,
2006) in neurons of the feeding control
circuits remains unknown.
Therefore, Plumandcolleaguescreated
a new mouse model of FoxO1 deficiency
restricted to POMC neurons and pituitary
cells (Plum et al., 2009). Major findings in
the mice were a phenotype of leanness,
decreased food intake under basal and
postfasting/refeeding conditions, but
unaltered energy expenditure, locomotor
activity, and corticosterone secretion.
Pomc-Foxo1/ mice were also partially
protected from weight gain induced by
a high-fat diet. Notably, despite the afore-
mentioned reports of Pomc serving as
an inhibitory target for FoxO1, there was
no evidence for increased Pomc mRNA
expression in the adult mutant mice under
basal conditions or upon refeeding after2009 Elsevier Inc.an 18 hr fast. However, the altered physio-
logical parameters were associated
with increased mediobasal hypothalamic
content of a-MSH compared to stable
Pomc precursor and ACTH levels and
an increased ratio of b-endorphin1-26
(b-End1-26) and b-End1-27 relative to the
more potent full-length b-End1-31 upon
refeeding. Consistent with this anorexi-
genic Pomc peptide profile, Cpe mRNA
levels were increased specifically in the
arcuate nucleus. Furthermore, wild-type
but not mutant mice fed a high-fat diet
exhibited a substantial decrease in Cpe
mRNA levels, while generalized over-
expression of Cpe in the arcuate nucleus
from an adenoviral vector mimicked the
attenuated refeeding response after a
fast that was observed in Pomc-Foxo1/
mice. In vitro studies using transfected
Neuro2A cells suggested that FoxO1
suppresses Cpe promoter activity by
acting as a corepressor independent of
direct DNA binding.
On the face of it, the paper lays out
a compelling argument for Cpe as a phys-
iologically meaningful nuclear target of
FoxO1 signaling. However, the absolute
magnitude of change in body weight,
body composition, and food intake in
Pomc-Foxo1/mice was relatively small
and the alterations in mediobasal
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measureable after a fasting, refeeding
paradigm and not under basal conditions.
Cell counts revealed a trend toward
decreased numbers of arcuate Pomc
neurons based on their identification by
in situ hybridization for Pomc mRNA. The
cause of this decrease is unknown, but in
any event, it would be expected to tip the
balance in favor of weight gain, not the
weight loss observed in Pomc-Foxo1/
mice. The final proof of altered Cpe
expression playing the proximate causa-
tive role in the phenotype may come
from a conditionally activated/inactivated
Cpe allele specifically in Pomc neurons. If
confirmed, drug development targeted at
Cpe to decrease appetite without
a compensatory drop in metabolic rate
may indeed be a rationale new approach
to the management of obesity and insulin
resistance, as suggested by the paper’s
authors.
A complementary study published in
the Journal of Clinical Investigation by
Wallingford and colleagues (Wallingford
et al., 2009) further highlights the potential
for targeted pharmacotherapy aimed at
modulation of Pomc posttranslational
processing to tweak Pomc circuits in
favor of an anorectic and catabolic
mode. The authors are the first to identify
a selective degradation pathway for
extracellular a-MSH involving the enzyme
prolylcarboxypeptidase (Prcp). Prcp was
identified as a candidate obesity gene
after positional cloning of the introgressedlocus from a lean, subcongenic mouse
strain. Recombinant enzyme efficiently
cleaved the amidated valine at residue
13 of a-MSH, converting it into the biolog-
ically dead peptide a-MSH1-12. Further-
more, an inactivating gene-trap mutation
in murine Prcp resulted in a lean pheno-
type with increased hypothalamic content
of a-MSH and an elevated a-MSH/ACTH
ratio. Pharmacologic inhibition of endoge-
nous Prcp in wild-type mice acutely
reduced food intake, consistent with
the chronic phenotype associated with
genetic deficiencies in Prcp. Based on
its localization in the hypothalamus, the
authors speculate that regulated release
of the enzyme from postsynaptic sites
on second order neurons may modulate
the strength of melanocortin signaling by
accelerated degradation of a-MSH.
In several aspects, the tale of these two
carboxypeptidases is analogous except
that Cpe cleaves Pomc-derived interme-
diates into a more potent anorexigenic
mix of peptides while Prcp terminates
a-MSH bioactivity by slicing just one
amino acid too deep. Both papers clearly
underscore the importance of quantifying
levels of all processed forms of Pomc
peptides, in addition to total peptide
levels and Pomc mRNA expression, to
fully understand the molecular basis of
associated phenotypes. The ultimate
step in linking altered Pomc peptide
profiles with biological function must
include development of more sophisti-
cated and sensitive technologies to simul-Cell Metabolism 10,taneously measure multiple peptides, not
just at the anatomic level of whole hypo-
thalamic areas under a static time frame
as performed in the two studies, but in
more discretely defined projection areas
of Pomc neurons and under dynamic
conditions.
REFERENCES
Cone, R.D. (2005). Nat. Neurosci. 8, 571–578.
Fukuda, M., Jones, J.E., Olson, D., Hill, J., Lee,
C.E., Gautron, L., Choi, M., Zigman, J.M., Lowell,
B.B., and Elmquist, J.K. (2008). J. Neurosci. 28,
13640–13648.
Gross, D.N., van den Heuvel, A.P., and Birnbaum,
M.J. (2008). Oncogene 27, 2320–2336.
Kim, M.S., Pak, Y.K., Jang, P.G., Namkoong, C.,
Choi, Y.S., Won, J.C., Kim, K.S., Kim, S.W., Kim,
H.S., Park, J.Y., et al. (2006). Nat. Neurosci. 9,
901–906.
Kitamura, T., Feng, Y., Kitamura, Y.I., Chua, S.C.,
Jr., Xu, A.W., Barsh, G.S., Rossetti, L., and Accili,
D. (2006). Nat. Med. 12, 534–540.
Plum, L., Lin, H.V., Dutia, R., Tanaka, J., Aizawa,
K.S., Matsumoto, M., Kim, A.J., Cawley, N.X.,
Paik, J.H., Loh, Y.P., et al. (2009). Nat. Med. 15,
1195–1201.
Pritchard, L.E., and White, A. (2007). Endocri-
nology 148, 4201–4207.
Wallingford, N., Perroud, B., Gao, Q., Coppola, A.,
Gyengesi, E., Liu, Z.W., Gao, X.B., Diament, A.,
Haus, K.A., Shariat-Madar, Z., et al. (2009).
J. Clin. Invest. 119, 2291–2303.
Yang, G., Lim, C.Y., Li, C., Xiao, X., Radda, G.K.,
Cao, X., and Han, W. (2009). J. Biol. Chem. 284,
3719–3727.November 4, 2009 ª2009 Elsevier Inc. 341
